---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000009"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:32:33.998375+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mineralys FY2022 net loss $29.8M; cash $110.1M plus $202M IPO; lorundrostat pivotal trials H1 2023

## Summary
- Net loss for FY2022 was $29.8M vs $19.4M in FY2021, driven by higher R&D and G&A costs.
- Cash and marketable securities were $110.1M at Dec 31, 2022; Feb 2023 IPO raised net ~$202M.
- Positive Phase 2 Target-HTN data presented; FDA end-of-Phase 2 meeting completed.
- Pivotal ADVANCE-HTN Phase 2 trial planned H1 2023; Phase 3 trial planned H2 2023.

## SEC filing metadata
- accession: 0001933414-23-000009
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000009/0001933414-23-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000009/mlys20230315-8kfy2022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000009
- JSON: https://secwatch.observer/filing/0001933414-23-000009.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000009.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported the full-year ended December 31, 2022 results: net income $29.8 million.
  - Period: the full-year ended December 31, 2022
  - Net income: $29.8 million
  - Result: reported results
  source text: Net loss was $29.8 million for the full year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000009/0001933414-23-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.